Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

Inclusion Criteria

• •1. Focal, segmental, or generalized (i.e., nonsegmental) stable vitiligo, defined as no new depigmented areas nor any depigmented areas that have expanded in size within the preceding 12 months.
• •2. The patient is a candidate for surgical intervention of a depigmented area, defined as a patient who has not satisfactorily responded to either:
• •1. topical therapy or
• •2. a minimum of 3 months of phototherapy.
• •3. The patient has a depigmented area available for treatment that is:
• •1. ≥90% depigmented,
• •2. without any other dermatologic conditions (other than vitiligo), and
• •3. excludes the lips, eyelids, plantar surface of feet, palmar surface of hands.
• •4. The patient is 18 years of age or older.
• •5. The patient agrees to remain on any current use of immunosuppressive therapy for the duration of his/her participation in the study (52 weeks).
• •6. The patient is willing and able to comply with post-treatment at-home phototherapy and all follow-up study visits.
• •7. The patient agrees to abstain from any other treatment of the study area for the duration of his/her participation in the study (52 weeks).
• •8. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation in the study (52 weeks).
• •9. In the opinion of the investigator, the patient must be able to:
• •1. Understand the full nature and purpose of the study, including possible risks and benefits,
• •2. Understand instructions and be able to comprehend and complete study questionnaires, and
• •3. Provide voluntary written informed consent. -